Trials / Conditions / Recurrent Adenoid Cystic Carcinoma of the Oral Cavity

Recurrent Adenoid Cystic Carcinoma of the Oral Cavity

18 registered clinical trials studyying Recurrent Adenoid Cystic Carcinoma of the Oral Cavity — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoi NCT02123511	Mayo Clinic	Phase 2
Completed	18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675	Sanjiv Sam Gambhir	Phase 1 / Phase 2
Terminated	Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer NCT01254734	City of Hope Medical Center	N/A
Completed	L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For NCT01155609	University of Washington	N/A
Completed	Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cance NCT01637194	Fox Chase Cancer Center	Phase 1
Recruiting	Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck NCT01473784	Ohio State University Comprehensive Cancer Center	N/A
Completed	Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Pri NCT00492089	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384	National Cancer Institute (NCI)	Phase 1
Completed	Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck NCT00470496	Roswell Park Cancer Institute	Phase 1
Completed	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland NCT00095563	National Cancer Institute (NCI)	Phase 2
Completed	Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362	National Cancer Institute (NCI)	Phase 1
Completed	Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Ad NCT00077428	National Cancer Institute (NCI)	Phase 2
Completed	Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can NCT00068497	National Cancer Institute (NCI)	N/A
Completed	Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498	National Cancer Institute (NCI)	Phase 1
Completed	7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and NCT00023959	National Cancer Institute (NCI)	Phase 1
Completed	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074	National Cancer Institute (NCI)	Phase 1